6. Parkinson disease Clinical trials / Disease details


Clinical trials : 2,298 Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-003796-17-GB
(EUCTR)
22/10/202001/09/2020A study to look at the effect of CST-103 or CST-139 on blood flow in the brain and on memory.An Open-Label Brain Imaging and Cognition Study to Determine Changes in Cerebral Perfusion and Cognition After Oral Administration of CST-103 or CST-139 Patients with Mild Cognitive Impairment or Parkinson’s Disease
MedDRA version: 21.1;Level: LLT;Classification code 10009846;Term: Cognitive impairment;System Organ Class: 10029205 - Nervous system disorders
MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Spiropent
Product Name: Clenbuterol HCl
Product Code: CST-103
INN or Proposed INN: CLENBUTEROL HYDROCHLORIDE
Trade Name: Berachin
Product Name: Tulobuterol
Product Code: CST-139
INN or Proposed INN: Tolubuterol Hydrochloride
Other descriptive name: TULOBUTEROL HYDROCHLORIDE
CuraSen Therapeutics, Inc.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
32Phase 2United Kingdom